JP2017527578A5 - - Google Patents

Download PDF

Info

Publication number
JP2017527578A5
JP2017527578A5 JP2017513450A JP2017513450A JP2017527578A5 JP 2017527578 A5 JP2017527578 A5 JP 2017527578A5 JP 2017513450 A JP2017513450 A JP 2017513450A JP 2017513450 A JP2017513450 A JP 2017513450A JP 2017527578 A5 JP2017527578 A5 JP 2017527578A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
irritable bowel
bowel syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017513450A
Other languages
English (en)
Japanese (ja)
Other versions
JP6538154B2 (ja
JP2017527578A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/056905 external-priority patent/WO2016038552A1/en
Publication of JP2017527578A publication Critical patent/JP2017527578A/ja
Publication of JP2017527578A5 publication Critical patent/JP2017527578A5/ja
Application granted granted Critical
Publication of JP6538154B2 publication Critical patent/JP6538154B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017513450A 2014-09-10 2015-09-09 Ret(rearranged during transfection)キナーゼ阻害剤としてのピリジン誘導体 Expired - Fee Related JP6538154B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2014086197 2014-09-10
CNPCT/CN2014/086197 2014-09-10
CN2015086995 2015-08-14
CNPCT/CN2015/086995 2015-08-14
PCT/IB2015/056905 WO2016038552A1 (en) 2014-09-10 2015-09-09 Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019102776A Division JP6728447B2 (ja) 2014-09-10 2019-05-31 Ret(rearranged during transfection)キナーゼ阻害剤としてのピリジン誘導体

Publications (3)

Publication Number Publication Date
JP2017527578A JP2017527578A (ja) 2017-09-21
JP2017527578A5 true JP2017527578A5 (enExample) 2018-10-25
JP6538154B2 JP6538154B2 (ja) 2019-07-03

Family

ID=54186249

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017513450A Expired - Fee Related JP6538154B2 (ja) 2014-09-10 2015-09-09 Ret(rearranged during transfection)キナーゼ阻害剤としてのピリジン誘導体
JP2019102776A Expired - Fee Related JP6728447B2 (ja) 2014-09-10 2019-05-31 Ret(rearranged during transfection)キナーゼ阻害剤としてのピリジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019102776A Expired - Fee Related JP6728447B2 (ja) 2014-09-10 2019-05-31 Ret(rearranged during transfection)キナーゼ阻害剤としてのピリジン誘導体

Country Status (36)

Country Link
US (4) US9918974B2 (enExample)
EP (2) EP3517526B1 (enExample)
JP (2) JP6538154B2 (enExample)
KR (1) KR20170045350A (enExample)
CN (1) CN107074768B (enExample)
AU (1) AU2015313841B2 (enExample)
BR (1) BR112017004900A2 (enExample)
CA (1) CA2960768A1 (enExample)
CL (1) CL2017000588A1 (enExample)
CO (1) CO2017002273A2 (enExample)
CR (1) CR20170093A (enExample)
CY (1) CY1121661T1 (enExample)
DK (1) DK3191450T3 (enExample)
DO (1) DOP2017000059A (enExample)
EA (1) EA033544B1 (enExample)
ES (2) ES2816453T3 (enExample)
HR (1) HRP20190815T1 (enExample)
HU (1) HUE044604T2 (enExample)
IL (1) IL250908B (enExample)
LT (1) LT3191450T (enExample)
MA (1) MA40581A (enExample)
ME (1) ME03432B (enExample)
MX (1) MX373863B (enExample)
MY (1) MY181913A (enExample)
PE (1) PE20170705A1 (enExample)
PH (1) PH12017500425B1 (enExample)
PL (1) PL3191450T3 (enExample)
PT (1) PT3191450T (enExample)
RS (1) RS58813B1 (enExample)
SG (1) SG11201701694QA (enExample)
SI (1) SI3191450T1 (enExample)
SM (1) SMT201900304T1 (enExample)
TW (1) TWI683807B (enExample)
UA (1) UA122213C2 (enExample)
UY (1) UY36293A (enExample)
WO (1) WO2016038552A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
BR112017004897A2 (pt) 2014-09-10 2017-12-12 Glaxosmithkline Ip Dev Ltd compostos inovadores como inibidores rearranjados durante a transfecção (ret)
EP3517526B1 (en) 2014-09-10 2020-08-19 GlaxoSmithKline Intellectual Property Development Limited Pyridinones as rearranged during transfection (ret) inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
AR107912A1 (es) 2016-03-17 2018-06-28 Blueprint Medicines Corp Inhibidores de ret
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド RETキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピラジン化合物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US20210290620A1 (en) 2017-05-15 2021-09-23 Blueprint Medicines Corporation Combinations of RET Inhibitors and mTORC1 Inhibitors and Uses Thereof for the Treatment of Cancer Mediated by Aberrant RET Activity
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
SG11202009681YA (en) 2018-04-03 2020-10-29 Blueprint Medicines Corp Ret inhibitor for use in treating cancer having a ret alteration
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
WO2021243192A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
CR20220666A (es) 2020-05-29 2023-05-05 Blueprint Medicines Corp Composiciones farmacéuticas de pralsetinib
TWI786742B (zh) * 2020-07-23 2022-12-11 大陸商深圳晶泰科技有限公司 吡啶酮類化合物及其製備方法和應用
CN119768181A (zh) 2022-08-24 2025-04-04 东丽株式会社 用于癌的治疗和/或预防的药品

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120046290A1 (en) 1997-12-22 2012-02-23 Jacques Dumas Inhibition of p38 kinase activity using substituted heterocyclic ureas
CA2315720A1 (en) 1997-12-22 1999-07-01 Bayer Corporation Inhibition of p38 kinase activity using substituted heterocyclic ureas
JP4437270B2 (ja) * 1997-12-22 2010-03-24 バイエル コーポレイション 置換複素環式尿素を用いたrafキナーゼの阻害
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
MXPA02001498A (es) 1999-08-12 2003-07-21 Pharmacia & Italia S P A Derivados de 3(5)-amino-pirazol, procedimiento para la preparacion de los mismos y usos como agentes antitumorales.
AU2002215053A1 (en) * 2000-11-27 2002-06-24 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
DE10201764A1 (de) 2002-01-18 2003-07-31 Bayer Cropscience Ag Substituierte 4-Aminopyridin-Derivate
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
JPWO2004024694A1 (ja) 2002-09-10 2006-01-05 杏林製薬株式会社 4−置換アリール−5−ヒドロキシイソキノリノン誘導体
CN1838958A (zh) 2003-08-22 2006-09-27 贝林格尔·英格海姆药物公司 治疗慢性阻塞性肺病和肺动脉高血压的方法
TW200530236A (en) * 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
PL1836169T3 (pl) * 2004-12-28 2012-07-31 Kinex Pharmaceuticals Llc Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
GB0507575D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US8247556B2 (en) * 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
TW200804349A (en) * 2005-12-23 2008-01-16 Kalypsys Inc Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases
ES2500165T3 (es) 2006-06-29 2014-09-30 Kinex Pharmaceuticals, Llc Composiciones de biarilo y métodos para modular una cascada de quinasas
WO2008033562A2 (en) * 2006-09-15 2008-03-20 Xcovery, Inc. Kinase inhibitor compounds
CN101558068A (zh) * 2006-10-16 2009-10-14 诺瓦提斯公司 用作蛋白激酶抑制剂的苯乙酰胺类
PL2848610T3 (pl) * 2006-11-15 2018-01-31 Ym Biosciences Australia Pty Inhibitory aktywności kinazy
KR20120059558A (ko) 2009-08-19 2012-06-08 암비트 바이오사이언시즈 코포레이션 바이아릴 화합물 및 이의 사용 방법
EP2651930B1 (en) 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Biarylamide inhibitors of leukotriene production
MX2015012286A (es) * 2013-03-15 2016-05-31 Glaxosmithkline Ip Dev Ltd Derivados de piridina como inhibidores de cinasa reordenada durante transfección.
AR095308A1 (es) 2013-03-15 2015-10-07 Glaxosmithkline Ip Dev Ltd Compuesto de 2-piridona, composición farmacéutica que lo comprende y su uso para preparar un medicamento
EP3517526B1 (en) 2014-09-10 2020-08-19 GlaxoSmithKline Intellectual Property Development Limited Pyridinones as rearranged during transfection (ret) inhibitors
BR112017004897A2 (pt) 2014-09-10 2017-12-12 Glaxosmithkline Ip Dev Ltd compostos inovadores como inibidores rearranjados durante a transfecção (ret)

Similar Documents

Publication Publication Date Title
JP2017526711A5 (enExample)
HRP20190815T1 (hr) Piridonski derivati korišteni kao inhibitori kinaze reorganizirane tijekom transfekcije (ret)
JP2013543896A5 (enExample)
JP2017528503A5 (enExample)
JP2013527202A5 (enExample)
JP2017504635A5 (enExample)
JP2017535550A5 (enExample)
JP2016503010A5 (enExample)
JP2018168191A5 (enExample)
JP2014525470A5 (enExample)
JP2015145426A5 (enExample)
NZ703941A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2015516434A5 (enExample)
JP2018518537A5 (enExample)
JP2015524472A5 (enExample)
JP2013526482A5 (enExample)
JP2017528507A5 (enExample)
JP2020510661A5 (enExample)
FI3699181T3 (fi) Kiteinen muoto (s)-n-(5-((r)-2-(2,5-diluorifenyyli)-pyrrolidin-1-yyli)-pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidivetyysulfaatista
JP2019512532A5 (enExample)
NZ627750A (en) Carbamate compounds and of making and using same
JP2014505107A5 (enExample)
JP2013523733A5 (enExample)
JP2014062126A5 (enExample)
JP2012507535A5 (enExample)